AHA 2020 Prof. Francis presents and interprets the findings of the SAMSON trial, in which symptom burden during statin, placebo and tablet-free periods was examined in patients who previously discontinued statins.
AHA 2020 Prevalence of silent CAD and identification of those with high risk of CAD were examined in the Swedish SCAPIS cohort.
AHA 2020 Prof. Bhatt responds to the presentation of the STRENGTH trial, in which the results were compared to those of REDUCE-IT. He addresses the differences in composition of the study drugs in the two trials.
AHA 2020 Prof. Pfeffer gives his perspective on therapeutic options for HFrEF patients, as an increasing number of drugs have demonstrated beneficial effects in this patient population.
AHA 2020 The STRENGTH trial, evaluating the combination of EPA and DHA, was stopped due to futility. Prof. Lincoff speculates why these results differ from those of the REDUCE-IT trial.
AHA 2020 A polypill may be an effective, safe and simple approach to reach lots of people to reduce the global burden of serious CVD. Prof. Salim Yusuf discusses the TIPS trial.
AHA 2020 Prof. Ponikowski presents the details of the AFFIRM-AHF trial, in which the effect of administration of IV ferric carboxymaltose shortly before discharge on clinical outcomes was examined in patients with acute HF and iron deficiency.
AHA 2020 Anthony Fauci gives a presentation on COVID-19: Public health and scientific challenges.
The recommendations in the 2019 ESC guidelines on management of diabetes and CVD have shifted from a glucose-centric approach towards an event-driven approach.
AHA 2020 The OMEMI trial found no beneficial effects on CV outcomes and all-cause death by omega-3 fatty acid supplementation in elderly patients after MI, compared to patients receiving placebo.
AHA 2020 The nonsteroidal MRA finerenone, evaluated in the FIDELIO-DKD trial, reduced the risk on renal and CV outcome compared to placebo in CKD and T2DM patients with or without a history of CVD.
AHA 2020 In individuals with intermediate CV risk and without CVD history, a combination of polypill plus aspirin reduced the primary outcome of CVD events compared to double placebo.